6946-11-8

Basic information

• Product Name: 2-oxopropane-1,3-diyl dibutanoate
• CAS NO: 6946-11-8
• Molecular Formula: C₁₁H₁₈O₅
• Molecular Weight: 230.2576
• Mol File: 6946-11-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 310.5°C at 760 mmHg
• Flash Point: 133.2°C
• Density: 1.075g/cm³
• Vapor Pressure: 0.000596mmHg at 25°C
• Refractive Index: 1.441
• CAS DataBase Reference: 2-oxopropane-1,3-diyl dibutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxopropane-1,3-diyl dibutanoate(6946-11-8)
• EPA Substance Registry System: 2-oxopropane-1,3-diyl dibutanoate(6946-11-8)

Safety Data

• Hazardous Substances Data: 6946-11-8(Hazardous Substances Data)

Upstream product

• 96-26-4 dihydroxyacetone 
• 141-75-3 butyryl chloride 
• 106-31-0 butanoic acid anhydride 
• 62147-49-3 1,3-dihydroxyacetone dimer 

Downstream Products

• 173837-48-4 1,3-di-n-butyryloxy-2-(2,4-difluorophenyl)-2-propanol 
• 173837-68-8 (R)-2-(2,4-difluorophenyl)-3-n-butyryloxy-1,2-propanediol 
• 101036-66-2 1,3-dibutyryl-2-palmitoylglycerol 

Relevant articles and documents

LIPID PRODRUGS OF NEUROSTEROIDS

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

DIETARY BUTYRATE FOR TREATING OR PREVENTING AN ALLERGIC DISORDER

A compound having the formula or combinations thereof, for use in the treatment or prevention of an allergic disorder, wherein R1, R2, R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.